Skip to search formSkip to main contentSkip to account menu

indium In 111 monoclonal antibody MN-14

Known as: In111 MOAB MN-14, In 111 monoclonal antibody MN-14, In 111 MOAB MN-14 
A radioimmunoconjugate of a murine monoclonal antibody, MoAb MN-14, labeled with indium 111 (In-111). MoAb Lym-1 recognizes an epitope of… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2000
Highly Cited
2000
UNLABELLED This phase I study was initiated to determine the toxicity and therapeutic potential of high-dose 131I-MN-14 F(ab)2… 
1999
1999
BACKGROUND Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for… 
1999
1999
Nine radioimmunotherapy (RAIT)-naive patients with medullary thyroid cancer received high doses of 131I-MN-14 F(ab)2 anti… 
1997
1997
OBJECTIVES Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen (CEA), and the plasma CEA level is… 
1997
1997
Advanced chemotherapy-resistant ovarian cancer has a poor prognosis, thus requiring new therapeutic modalities. A complete… 
1996
1996
The initial clinical experience with the second‐generation, high‐affinity, MN‐14 immunoglobulin (IgG) anticarcinoembryonic… 
1995
1995
The targeting potential of 131I-labeled NP-4 and MN-14 anti-CEA (carcinoembryonic antigen) monoclonal antibodies (MAbs) was… 
1995
1995
Myelosuppressive toxicity is dose-limiting for radioimmunotherapy. We have reported on the use of cytokine intervention (rhIL-1… 
1990
1990
Tumor targeting of five radioiodinated murine monoclonal antibodies (MAbs) directed against human colorectal cancer were studied…